Poniard Pharmaceuticals, Inc. (PARD)
Poniard Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Seattle, WA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $150. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of -36.63 implies it has historically moved less than the broad market.
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
Poniard Pharmaceuticals, Inc. is most often compared with the following Healthcare names: